Commentary
Commentary on “MiRNA Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neoadjuvant Chemoradiotherapy”
Translational Cancer Research
2017;
6
(Suppl 1)
:S1-S2
.
(28 February 2017)
Association between hypomethylation of specific smoking-related CpG sites and lung cancer
Translational Cancer Research
2017;
6
(Suppl 1)
:S3-S4
.
(28 February 2017)
Expelling the “perpetrators”: ovarian cancer cells discard miR-6126 through exosomes to promote survival
Translational Cancer Research
2017;
6
(Suppl 1)
:S5-S7
.
(28 February 2017)
Metabolites-mitochondria-macrophages (MMM): new therapeutic avenues for inflammation and muscle atrophy
Translational Cancer Research
2017;
6
(Suppl 1)
:S8-S11
.
(28 February 2017)
A microRNA molecular signature of aggressive prostate cancer
Translational Cancer Research
2017;
6
(Suppl 1)
:S12-S14
.
(28 February 2017)
KRAS mutations: efficacy and sensitivity of early predictive screening of cancer progression require other gene mutations in addition to KRAS
Translational Cancer Research
2017;
6
(Suppl 1)
:S15-S17
.
(28 February 2017)
MOAP-1, UBR5 and cisplatin resistance in ovarian cancer
Translational Cancer Research
2017;
6
(Suppl 1)
:S18-S21
.
(28 February 2017)
Immunosuppressive role of γδ T cells in cancer: the other side of the coin
Translational Cancer Research
2017;
6
(Suppl 1)
:S22-S25
.
(28 February 2017)
The vestibular approach in transoral thyroid surgery: proceedings within the clinical setting
Translational Cancer Research
2017;
6
(Suppl 1)
:S26-S28
.
(28 February 2017)
Interaction of tumor and stromal cells in pancreatic cancer
Translational Cancer Research
2017;
6
(Suppl 1)
:S29-S30
.
(28 February 2017)
High dose Bacillus Calmette-Guerin (BCG) for urothelial carcinoma is trickier than expected
Translational Cancer Research
2017;
6
(Suppl 1)
:S31-S32
.
(28 February 2017)
CD274 (PD-L1) genomic change: another marker for small-cell lung cancer?
Translational Cancer Research
2017;
6
(Suppl 1)
:S33-S35
.
(28 February 2017)
Cleaning up the environment in juvenile myelomonocytic leukemia
Translational Cancer Research
2017;
6
(Suppl 1)
:S36-S38
.
(28 February 2017)
Estimated risks of recurrence and mortality in lung cancer: comprehensive analysis by a population-based study
Translational Cancer Research
2017;
6
(Suppl 1)
:S39-S41
.
(28 February 2017)
Defining the subset of the patients in whom “Less is More” for hormone receptor-positive breast cancer: clinical risk vs. genomics risk
Translational Cancer Research
2017;
6
(Suppl 1)
:S42-S43
.
(28 February 2017)
CRISPR made easy in human and murine hematopoietic precursors
Translational Cancer Research
2017;
6
(Suppl 1)
:S44-S46
.
(28 February 2017)
Molecular heterogeneity of localized prostate cancer: more different than alike
Translational Cancer Research
2017;
6
(Suppl 1)
:S47-S50
.
(28 February 2017)
Early detection of lung cancer based on DNA methylation analysis in sputum and plasma
Translational Cancer Research
2017;
6
(Suppl 1)
:S51-S53
.
(28 February 2017)
Differential crizotinib response duration among ALK fusion variants in ALK-positive non–small-cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 1)
:S54-S56
.
(28 February 2017)
Inhibit a kinase to degrade a histone demethylase: a candidate therapeutic approach in glioblastoma
Translational Cancer Research
2017;
6
(Suppl 1)
:S57-S60
.
(28 February 2017)
Plasma genotyping for EGFR T790M in non-small cell lung cancer: ready for clinical practice?
Translational Cancer Research
2017;
6
(Suppl 1)
:S61-S64
.
(28 February 2017)
Genetic footprints of T cell exhaustion
Translational Cancer Research
2017;
6
(Suppl 1)
:S65-S67
.
(28 February 2017)
Shelterin genes, germ line mutations and chronic lymphocytic leukemia
Translational Cancer Research
2017;
6
(Suppl 1)
:S68-S71
.
(28 February 2017)
Mutations in KRAS: are they a valid biomarker for pancreatic ductal adenocarcinomas diagnosis?
Translational Cancer Research
2017;
6
(Suppl 1)
:S72-S77
.
(28 February 2017)
A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 1)
:S78-S82
.
(28 February 2017)
Exportin 1/chromosome region maintenance 1 as a therapeutic target for lung cancer
Translational Cancer Research
2017;
6
(Suppl 1)
:S83-S86
.
(28 February 2017)
Glioblastoma stem cells and the importance of endolysosomes to keep them in the niches
Translational Cancer Research
2017;
6
(Suppl 1)
:S87-S89
.
(28 February 2017)
The role of tumor-derived exosomes in epithelial mesenchymal transition (EMT)
Translational Cancer Research
2017;
6
(Suppl 1)
:S90-S92
.
(28 February 2017)
KDM4B under hypoxia: a new targetable pathway for epithelial ovarian cancer?
Translational Cancer Research
2017;
6
(Suppl 1)
:S93-S95
.
(28 February 2017)
Proton beam therapy as a rising option in treating intrahepatic cholangiocarcinoma
Translational Cancer Research
2017;
6
(Suppl 1)
:S96-S98
.
(28 February 2017)
Editorial
Extremely low dose 18F-FDG PET imaging and its potential use for lung cancer screening
Translational Cancer Research
2017;
6
(Suppl 1)
:S99-S101
.
(28 February 2017)
Beyond immune suppression: the intrinsic function of PD-L1 in ovarian cancer and melanoma
Translational Cancer Research
2017;
6
(Suppl 1)
:S102-S103
.
(28 February 2017)
Neuroendocrine differentiation in prostate cancer: key epigenetic players
Translational Cancer Research
2017;
6
(Suppl 1)
:S104-S108
.
(28 February 2017)
Targeting the pyrimidine synthesis pathway for differentiation therapy of acute myelogenous leukemia
Translational Cancer Research
2017;
6
(Suppl 1)
:S109-S111
.
(28 February 2017)
Oligometastatic disease in prostate cancer, a continuously changing paradigm: patient selection and treatment strategy
Translational Cancer Research
2017;
6
(Suppl 1)
:S112-S116
.
(28 February 2017)
Osimertinib: a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma
Translational Cancer Research
2017;
6
(Suppl 1)
:S117-S121
.
(28 February 2017)
DNA methylation biomarkers in lung cancer diagnosis: closer to practical use?
Translational Cancer Research
2017;
6
(Suppl 1)
:S122-S126
.
(28 February 2017)
Revealing the mutational landscape of APL
Translational Cancer Research
2017;
6
(Suppl 1)
:S127-S130
.
(28 February 2017)
Looking into the future (remnant liver)
Translational Cancer Research
2017;
6
(Suppl 1)
:S131-S135
.
(28 February 2017)
Gene signatures predictive of response to radiotherapy in prostate cancer: a new step towards precision medicine
Translational Cancer Research
2017;
6
(Suppl 1)
:S136-S140
.
(28 February 2017)
Immunotherapy, checkpoint inhibitor advance to frontline non-small cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 1)
:S141-S144
.
(28 February 2017)
Heparin-induced thrombocytopenia: new insights into the immune response
Translational Cancer Research
2017;
6
(Suppl 1)
:S145-S148
.
(28 February 2017)
Subsequent treatment(s) for prostate cancer recurrence following radical prostatectomy deteriorate functional outcome and quality of life
Translational Cancer Research
2017;
6
(Suppl 1)
:S149-S150
.
(28 February 2017)
Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease
Translational Cancer Research
2017;
6
(Suppl 1)
:S151-S157
.
(28 February 2017)
Prognosis in glioblastoma: insight gained from recent prospective trials
Translational Cancer Research
2017;
6
(Suppl 1)
:S158-S159
.
(28 February 2017)
Taming immune suppressor: application of myeloid-derived suppressor cells in anti-cancer gene therapy
Translational Cancer Research
2017;
6
(Suppl 1)
:S160-S162
.
(28 February 2017)
Perspective
Oxaliplatin in pre-treated patients: maybe not the match point?
Translational Cancer Research
2017;
6
(Suppl 1)
:S163-S167
.
(28 February 2017)
Bacillus Calmette-Guérin immunotherapy—increasing dose as a means of improving therapy?
Translational Cancer Research
2017;
6
(Suppl 1)
:S168-S173
.
(28 February 2017)
Transoral thyroidectomy—from experiment to clinical implementation
Translational Cancer Research
2017;
6
(Suppl 1)
:S174-S178
.
(28 February 2017)
Is dose-dependent response to bacillus Calmette-Guérin treatment in urothelial carcinoma?
Translational Cancer Research
2017;
6
(Suppl 1)
:S179-S181
.
(28 February 2017)
Metabolic sculpting of the mitochondria, cell signaling and the cancer phenotype
Translational Cancer Research
2017;
6
(Suppl 1)
:S182-S188
.
(28 February 2017)
A core of macrophages facilitates ovarian cancer metastases
Translational Cancer Research
2017;
6
(Suppl 1)
:S189-S196
.
(28 February 2017)
Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer?
Translational Cancer Research
2017;
6
(Suppl 1)
:S197-S200
.
(28 February 2017)
The practice-changing QUARTZ trial: is there any role for whole brain radiotherapy in patients with non-small cell lung cancer and brain metastases?
Translational Cancer Research
2017;
6
(Suppl 1)
:S201-S204
.
(28 February 2017)
CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer
Translational Cancer Research
2017;
6
(Suppl 1)
:S205-S209
.
(28 February 2017)
Beyond international prognostic index: risk stratification in diffuse large B-cell lymphoma
Translational Cancer Research
2017;
6
(Suppl 1)
:S210-S216
.
(28 February 2017)
The metastatic niche in the liver: tilling the soil for pancreatic cancer progression
Translational Cancer Research
2017;
6
(Suppl 1)
:S217-S220
.
(28 February 2017)
Are bladder cancer patients set at risk by minimally invasive approaches to radical cystectomy?
Translational Cancer Research
2017;
6
(Suppl 1)
:S221-S225
.
(28 February 2017)
Correspondence
Exosomes: an evolving source of urinary biomarkers and an up-and-coming therapeutic delivery vehicle
Translational Cancer Research
2017;
6
(Suppl 1)
:S226-S228
.
(28 February 2017)
The prospective role of matrix metalloproteinase-2/9 and transforming growth factor beta 1 in accelerating the progression of hepatocellular carcinoma
Translational Cancer Research
2017;
6
(Suppl 1)
:S229-S231
.
(28 February 2017)
miRNA-based signature for predicting epithelial ovarian cancer recurrence
Translational Cancer Research
2017;
6
(Suppl 1)
:S232-S234
.
(28 February 2017)
Disclosure:
This supplement was published without any sponsorship or funding.